Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))

Dotan Moskovich; Adi Alfandari; Yael Finkelshtein; Avivit Weisz; Aviva Katzav; Debora Kidron; Evgeny Edelstein; Daniel Veroslavski; Ruth Perets; Nissim Arbib; Yfat Kadan; Ami Fishman; Bernard Lerer; Martin Ellis; Osnat Ashur-Fabian

doi:10.1016/j.canlet.2023.216196

Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))

Dotan Moskovich, Adi Alfandari, Yael Finkelshtein, Avivit Weisz, Aviva Katzav, Debora Kidron, Evgeny Edelstein, Daniel Veroslavski, Ruth Perets, Nissim Arbib, Yfat Kadan, Ami Fishman, Bernard Lerer, Martin Ellis, Osnat Ashur-Fabian^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.

Original language	English
Article number	216196
Journal	Cancer Letters
Volume	563
DOIs	https://doi.org/10.1016/j.canlet.2023.216196
State	Published - 1 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2023.216196

Fingerprint

Dive into the research topics of 'Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))'. Together they form a unique fingerprint.

Cite this

Moskovich, D., Alfandari, A., Finkelshtein, Y., Weisz, A., Katzav, A., Kidron, D., Edelstein, E., Veroslavski, D., Perets, R., Arbib, N., Kadan, Y., Fishman, A., Lerer, B., Ellis, M., & Ashur-Fabian, O. (2023). Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011)). Cancer Letters, 563, Article 216196. https://doi.org/10.1016/j.canlet.2023.216196

Moskovich, Dotan ; Alfandari, Adi ; Finkelshtein, Yael et al. / Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011)). In: Cancer Letters. 2023 ; Vol. 563.

@article{e26215a9f6d94f1babc467824c0deaa9,

title = "Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))",

abstract = "In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.",

author = "Dotan Moskovich and Adi Alfandari and Yael Finkelshtein and Avivit Weisz and Aviva Katzav and Debora Kidron and Evgeny Edelstein and Daniel Veroslavski and Ruth Perets and Nissim Arbib and Yfat Kadan and Ami Fishman and Bernard Lerer and Martin Ellis and Osnat Ashur-Fabian",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = jun,

day = "1",

doi = "10.1016/j.canlet.2023.216196",

language = "אנגלית",

volume = "563",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

}

Moskovich, D, Alfandari, A, Finkelshtein, Y, Weisz, A, Katzav, A, Kidron, D, Edelstein, E, Veroslavski, D, Perets, R, Arbib, N, Kadan, Y, Fishman, A, Lerer, B, Ellis, M & Ashur-Fabian, O 2023, 'Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))', Cancer Letters, vol. 563, 216196. https://doi.org/10.1016/j.canlet.2023.216196

Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011)). / Moskovich, Dotan; Alfandari, Adi; Finkelshtein, Yael et al.
In: Cancer Letters, Vol. 563, 216196, 01.06.2023.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))

AU - Moskovich, Dotan

AU - Alfandari, Adi

AU - Finkelshtein, Yael

AU - Weisz, Avivit

AU - Katzav, Aviva

AU - Kidron, Debora

AU - Edelstein, Evgeny

AU - Veroslavski, Daniel

AU - Perets, Ruth

AU - Arbib, Nissim

AU - Kadan, Yfat

AU - Fishman, Ami

AU - Lerer, Bernard

AU - Ellis, Martin

AU - Ashur-Fabian, Osnat

PY - 2023/6/1

Y1 - 2023/6/1

N2 - In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.

AB - In the original manuscript, there was an error in the name of one of the cell lines. Instead of OVCAR3 it should have been ES-2. This was amended in the published article and the supplementary material.

UR - http://www.scopus.com/inward/record.url?scp=85153290915&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2023.216196

DO - 10.1016/j.canlet.2023.216196

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 37104919

AN - SCOPUS:85153290915

SN - 0304-3835

VL - 563

JO - Cancer Letters

JF - Cancer Letters

M1 - 216196

ER -

Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D et al. Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011)). Cancer Letters. 2023 Jun 1;563:216196. doi: 10.1016/j.canlet.2023.216196

Corrigendum to “DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer” [Canc. Lett. 501 224–233] (Cancer Letters (2021) 501 (224–233), (S0304383520306030), (10.1016/j.canlet.2020.11.011))

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this